Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Propanc Biopharma, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cost of revenue
0.03
0.03
0.03
Research and development
0.97
1.83
0.26
0.18
0.23
0.26
0.25
0.25
0.22
0.63
General and administrative
4.74
2.1
2.33
3.28
1.55
1.71
1.5
1.25
0.11
0.67
Operating expenses
5.74
3.96
2.61
3.49
1.81
1.99
1.78
1.54
57.3
18.2
Operating income
-5.74
-3.96
-2.61
-3.49
-1.81
-1.99
-1.78
-1.54
-57.3
-18.2
Interest expense
3.2
2.79
1.31
1.75
0.45
0.57
0.53
0.67
0.56
0.43
Interest income
0
0
0
0
0
0.01
0
0
0
0
Other non-operating income
-2.43
-3.26
-3.26
-1.38
-0.33
-0.72
-1.01
-0.41
-1.65
-0.68
Pre-tax income
-8.17
-7.04
-5.76
-4.88
-2.14
-2.71
-2.79
-1.95
-58.9
-18.9
Income tax
-0.31
-0.18
-0.12
-0.13
-0.11
-0.05
-0.13
-0.13
Net income
-7.87
-7.04
-5.76
-4.74
-2.03
-2.66
-2.66
-1.82
-58.9
-18.9
EBITDA
-5.74
-3.96
-2.61
-3.49
-1.81
-1.99
-1.77
-1.54
-18.2
EPS, basic
-2,000,234,880,000.00
-321,465,787,500.00
-19,728,557,700.00
-341,698,824.00
-1,420,416.00
-87,408,850.00
-3,195,936.00
-35,510.00
-371.22
-17.62
EPS, diluted
-2,000,235,862,670.00
-321,466,477,929.00
-19,728,600,072.00
-341,698,634.00
-1,420,415.00
-87,408,801.00
-3,195,934.00
-35,510.00
-371.22
-17.62
Shares, basic (weighted)
0
0
0
0
0
0
0
0
0.16
1.12
Shares, diluted (weighted)
0
0
0
0
0
0
0
0
0.16
1.12
Balance sheet
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
0.07
0.02
0
0.07
0
0
0.01
0.02
0.01
0.83
Other current assets
0
0.03
0.08
0.01
0.01
0
0
0.03
Total current assets
0.08
0.06
0.09
0.07
0.01
0.02
0.02
0.03
8.35
8.54
Property, plant and equipment
0.01
0.01
0.01
0.01
0
0
0
0
Lease right-of-use assets
0.02
0.06
0.02
0.06
0.04
Total assets
0.1
0.07
0.1
0.1
0.01
0.08
0.06
0.07
19.6
12.8
Accounts payable
0.48
1.16
0.92
0.84
1
0.94
0.97
1.21
1.25
1.13
Accrued liabilities
0.12
0.14
0.32
0.35
0.42
0.42
0.59
0.64
0.67
0.75
Total current liabilities
5.54
6.82
4.4
3.74
3.08
3.06
3.16
3.79
5.58
3.35
Lease liabilities
0.04
0.04
0.02
Total liabilities
5.54
6.82
4.4
3.74
3.08
3.11
3.18
3.85
5.73
3.38
Total debt
3.48
4.7
1.66
1.56
0.62
0.93
0.39
0.4
0.54
Paid-in capital
33
38.2
45.7
50.9
54.1
57.4
60.3
61.7
138
153
Retained earnings
-38.2
-45.3
-51
-55.8
-58.2
-61.6
-64.7
-66.7
-126
-144
Treasury stock
-0.05
-0.05
-0.05
-0.05
-0.05
-0.05
-0.05
-0.05
-0.05
-0.05
Other comprehensive income
-0.14
0.36
1.07
1.27
1.09
1.23
1.29
1.27
1.32
1.18
Shareholders' equity
-5.44
-6.75
-4.3
-3.64
-3.07
-3.02
-3.12
-3.78
13.9
9.4
Total equity
-5.44
-6.75
-4.3
-3.64
-3.07
-3.02
-3.12
-3.78
13.9
9.4
Total liabilities and equity
0.1
0.07
0.1
0.1
0.01
0.08
0.06
0.07
19.6
12.8
Shares outstanding
0
0
0
0
0
0
0
0
0.46
3.31
Cash flow statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
-7.87
-7.04
-5.76
-4.74
-2.03
-2.66
-2.66
-1.82
-58.9
-18.9
Depreciation and amortization
0
0
0
0
0
0
0
0
0
Stock-based compensation
1.69
0.52
0.3
0.08
0.07
0
4.62
8.5
Change in receivables
0.02
0
0
0
-0
0
-0
-0
-0
-0.01
Change in payables
0.15
0.73
-0.16
-0.06
0.18
0.02
0.08
0.24
0.19
-0.18
Cash from operations
-2.05
-2.18
-2.06
-1.85
-1.15
-1.44
-1.11
-0.94
-0.41
-5.68
Capital expenditures
-0
-0
Cash from investing
-0
-0
Debt repaid
-0
-0.12
-0.67
Stock issued
1.1
0.45
0.1
0.02
0.02
3.31
Cash from financing
2.1
2.4
2.12
1.89
1.06
1.49
1.11
0.94
0.49
6.46
Exchange rate effect
-0.1
-0.27
-0.07
Net change in cash
-0.05
-0.02
0.06
-0.06
0
0.01
0.01
-0.01
0.82
Free cash flow
-2.06
-5.69
Interest paid
0
0.02
0.1
0.01
0.01
0
0
0.01
0.03
0.13
Key metrics
Worked out from the statements above. Latest values use fiscal 2026. Valuation uses the share price of $0.63 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-161.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-116.4%
Net income / average total assets.
Return on invested capital (ROIC)
-124.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-32.4%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-34.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
496.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
296.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
608.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
10,296.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
1,312.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.55x
Current assets / current liabilities.
Quick ratio
0.25x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.25x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$17.62
Net income per basic share, as reported (split-adjusted).
FCF per share
-$5.06
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$5.06
Cash from operations / diluted weighted shares.
Book value per share
$2.84
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.23x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.23x
Market cap / tangible book value, when positive.
FCF yield
-257.5%
Free cash flow / market cap.
Earnings yield
-854.0%
Net income / market cap (the inverse of P/E).
Was Propanc Biopharma, Inc. profitable in fiscal 2026?
No. It reported a net loss of $18.9M.
How much free cash flow did Propanc Biopharma, Inc. generate in fiscal 2026?
Cash from operations of $5.7M minus capital expenditures of $4.9K left free cash flow of -$5.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.